Consensus Progyny, Inc.

Stocks

PGNY

US74340E1038

Managed Healthcare

Market Closed - Nasdaq 16:00:00 2026-09-21 EDT			5-day change	1st Jan Change
26.86 ^USD	-1.00%		-3.55%	+4.60%

09-14	Progyny Insider Sold Shares Worth $321,358, According to a Recent SEC Filing	MT
08-20	Wells Fargo Initiates Progyny at Overweight With $37 Price Target	MT

Evolution of the Average Target: Progyny, Inc.

Evolution of the Target Price: Progyny, Inc.

Changes in Analyst Recommendations: Progyny, Inc.

a9100a9668775b3b106683.dWN5O3o218uSo_AhkMy_m3v8QBtUve9e3t7Pg0PVRBQ.MVY6aglvr_Oj8shq56fs9i64cFQA34MZi5Cs5QGlCUUTKwtJO2SwhufImw~e3bd07c7e2464eae1c02504bda04f75b

Analysts' recommendations: Progyny, Inc.

08-20	Wells Fargo Initiates Progyny at Overweight With $37 Price Target	MT
08-13	Truist Adjusts Price Target on Progyny to $36 From $33, Maintains Buy Rating	MT
07-28	Progyny Shares Drop After Downgrade From Barclays	MT
07-28	Barclays Downgrades Progyny to Equalweight From Overweight, Adjusts Price Target to $34 From $27	MT
06-22	Truist Adjusts Price Target on Progyny to $33 From $30, Maintains Buy Rating	MT
05-19	Canaccord Genuity Upgrades Progyny to Buy From Hold, Adjusts PT to $30 From $19	MT
05-11	Truist Raises Price Target on Progyny to $30 From $28, Keeps Buy Rating	MT
03-02	Truist Cuts Price Target on Progyny to $28 From $34, Keeps Buy Rating	MT
11-12	Progyny Shares Rise After KeyBanc Upgrade	MT
11-12	KeyBanc Upgrades Progyny to Overweight From Sector Weight, Sets $30 Price Target	MT
11-11	Truist Raises Price Target on Progyny to $28 From $27, Keeps Hold Rating	MT
25-03-31	BTIG Upgrades Progyny to Buy From Neutral, Price Target is $28	MT
25-02-05	Truist Securities Adjusts Progyny Price Target to $24 From $19, Maintains Hold Rating	MT
24-12-02	JPMorgan Downgrades Progyny to Neutral, Price Target is $17	MT
24-11-13	Jefferies Adjusts Progyny Price Target to $19 From $24, Maintains Buy Rating	MT
24-11-13	Truist Downgrades Progyny to Hold From Buy, Cuts Price Target to $19 From $26	MT
24-09-19	Jefferies Cuts Price Target on Progyny to $24 From $31, Buy Rating Maintained	MT
24-09-19	Truist Cuts Price Target on Progyny to $26 From $33, Maintains Buy Rating	MT
24-09-19	JMP Securities Downgrades Progyny to Market Perform From Outperform	MT
24-08-07	Truist Securities Adjusts Progyny Price Target to $33 From $37, Maintains Buy Rating	MT
24-08-07	Canaccord Genuity Downgrades Progyny to Hold From Buy, Cuts Price Target to $24 From $37	MT
24-08-07	BTIG Downgrades Progyny to Neutral From Buy; Shares Fall Pre-Bell	MT
24-08-07	Leerink Downgrades Progyny to Market Perform From Outperform, Cuts Price Target to $25 From $31	MT
24-07-16	JMP Securities Initiates Progyny at Outperform With $36 Price Target	MT
24-05-17	Truist Securities Cuts Price Target on Progyny to $37 From $46, Keeps Buy Rating	MT

More recommendations

Other Managed Healthcare

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PROGYNY, INC.					+26.86%
	UNITEDHEALTH GROUP INC.					+27.81%
	ELEVANCE HEALTH, INC.					+9.84%
	CIGNA					+23.28%
	HUMANA INC.					+8.5%
	CENTENE CORPORATION					+10.24%
	MOLINA HEALTHCARE, INC.					+4.15%
	CLOVER HEALTH INVESTMENTS, CORP.					+20.52%
	ALIGNMENT HEALTHCARE, INC.					+166.24%
	Average					+33.05%
	Weighted average by Cap.					+22.07%